Chinese researchers develop cell therapy for heart failure patients
Chinese researchers have recently developed a new cardiac cell therapy that helps repair damaged myocardium and improve heart function in patients with severe heart failure, Xinhua reported.
Pioneered by Nanjing Drum Tower Hospital in Jiangsu Province, eastern China, the therapy uses lab-cultured cardiomyocytes to replace necrotic heart tissue, enabling blood vessel recanalisation alongside myocardial regeneration.
“Bypass surgery can reopen blocked blood vessels, but it cannot regrow dead myocardium,” said Professor Wang Dongjin, who led the research, to Xinhua. He added that the new therapy is designed to address this problem. “We want to inject new cardiomyocytes directly into the heart to replace dead muscle and restore its function. It is like the ancient Chinese saying: what is lacking, that is what is eaten.”
Long-term follow-up results from the clinical study were published on 19 August in the journal Nature Medicine.
Twelve-month follow-up data showed that 90 per cent of patients receiving the cell therapy recovered to New York Heart Association (NYHA) functional class II. Patients reported significantly reduced shortness of breath and chest tightness during daily activities. Meanwhile, in the control group that underwent bypass surgery alone, the recovery rate was 60 per cent.
Patients in the cell therapy group also recorded an average improvement of 168.8 metres in the six-minute walk test, nearly double the improvement seen in the control group. The difference in heart pumping function was even more pronounced: stroke volume increased in the cell therapy group but decreased in the control group.
“For the first time, we have proven that this therapy is safe,” said Wang. During the follow-up period, no patients developed tumours or experienced recurrent malignant arrhythmias. “We also confirmed that the transplanted cells beat in synchrony with the patient’s own heart rhythm. This is an important validation at the global level.”
The cell product used in the clinical trial, HiCM-188, is an off-the-shelf therapy that can be manufactured and stored in standardised production batches, avoiding the lengthy customisation process required for patient-specific cell products. This is a crucial advantage given that heart transplantation is unaffordable for most end-stage heart failure patients due to the persistent scarcity of donors.
“Instead of patients waiting for cells to become available, we want the cells to be ready and waiting for patients,” said Wang. “This could fundamentally alleviate the donor shortage crisis.”
Industry experts said that although the sample size is limited, the rigorous randomised controlled clinical trial design provides strong proof of concept, placing China’s cardiac regenerative medicine at the global forefront.
With larger-scale clinical trials in the future, this domestically developed Chinese therapy has the potential to transform the treatment paradigm for severe heart failure and benefit many patients, the experts said.
Source: jawawa.id (https://jawawa.id/newsitem/chinese-researchers-develop-cell-therapy-for-heart-failure-patients-1787766693)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5712697/peneliti-china-kembangkan-terapi-sel-untuk-pasien-gagal-jantung), translated from Indonesian